Constellation Pharmaceuticals (CNST) Releases Earnings Results, Misses Estimates By $0.14 EPS

Constellation Pharmaceuticals (NASDAQ:CNST) issued its earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.14), Fidelity Earnings reports.

CNST stock traded down $0.23 during midday trading on Friday, reaching $5.86. 6,229 shares of the company’s stock traded hands, compared to its average volume of 19,381. Constellation Pharmaceuticals has a 1-year low of $5.57 and a 1-year high of $12.21.

CNST has been the subject of a number of recent research reports. Cann initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $21.00 target price for the company. BMO Capital Markets initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $19.00 target price for the company. JPMorgan Chase & Co. initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “overweight” rating and a $17.00 target price for the company. Oppenheimer initiated coverage on Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Zacks Investment Research raised Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a report on Monday, October 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Constellation Pharmaceuticals has an average rating of “Buy” and an average target price of $17.15.

TRADEMARK VIOLATION NOTICE: “Constellation Pharmaceuticals (CNST) Releases Earnings Results, Misses Estimates By $0.14 EPS” was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/2018/11/10/constellation-pharmaceuticals-cnst-releases-earnings-results-misses-estimates-by-0-14-eps.html.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Recommended Story: Understanding the different types of bonds

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply